Safety and efficacy of apremilast in adults hospitalized with COVID-19
M. Jain (Chicago, United States), M. Bacci (Santo Andre, Brazil), A. Gavrylov (Kharkiv, Ukraine), B. Hochberger (Osorno, Chile), S. Alvarez (Tijuana, Mexico), T. Alvarez (Rosario, Argentina), J. Persichino (Riverside, United States), P. Charuworn (Thousand Oaks, United States), C. Milmont (Thousand Oaks, United States), R. Zhang (Thousand Oaks, United States), R. Elenjical (Centurion, South Africa)
Source: International Congress 2022 – COVID treatments
Session: COVID treatments
Session type: Thematic Poster
Number: 2595
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Jain (Chicago, United States), M. Bacci (Santo Andre, Brazil), A. Gavrylov (Kharkiv, Ukraine), B. Hochberger (Osorno, Chile), S. Alvarez (Tijuana, Mexico), T. Alvarez (Rosario, Argentina), J. Persichino (Riverside, United States), P. Charuworn (Thousand Oaks, United States), C. Milmont (Thousand Oaks, United States), R. Zhang (Thousand Oaks, United States), R. Elenjical (Centurion, South Africa). Safety and efficacy of apremilast in adults hospitalized with COVID-19. 2595
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|